
Opinion|Videos|May 21, 2024
Optimizing Transitions of Care for Hepatic Encephalopathy Patients
Key opinion leaders emphasize crucial factors for pharmacists to consider, such as medication costs, staying updated on the latest hepatic encephalopathy (HE) clinical advancements and trials, and understanding disease incidence, which can help prevent recurrence, reduce healthcare costs, and improve patients' cognitive function when managed effectively.
Advertisement
Episodes in this series

Advertisement
Related to this article

Before lung cancer therapy begins, diagnostic findings and treatment readiness shape care, creating opportunities for pharmacists to help patients start safely.

October’s pain management coverage examined postoperative suzetrigine, pharmacist follow-up for cancer-related neuropathic pain, constipation prevention, and counseling patients concerned about prescribed opioids.

CDC surveillance data show that approximately 10% of adults hospitalized with RSV died during hospitalization or within 60 days of discharge.

VAX-31 met all primary immunogenicity end points against PCV20 and PCV21 in the pivotal OPUS-1 trial.

October’s hematology coverage highlighted first-line pirtobrutinib, questions about myeloma treatment duration and early intervention, and pharmacists’ roles in medication safety and access.

October’s oncology coverage highlighted new treatment options in rectal, breast, and prostate cancers, alongside longer-term survival findings and concerns about reduced-frequency immunotherapy.

Young adults who vaped daily but never smoked had lower flow-mediated dilation and peak oxygen uptake than peers who used neither product.
Advertisement
Advertisement
Trending on Pharmacy Times
1
October 2026 in Pain Management: 4 Updates on Treatment and Pharmacy Practice
2
What Happens Before the First Dose? 5 Steps That Shape Lung Cancer Treatment
3
Nicotine Vaping Linked to Lower Vascular Function in Young Adults
4
Over Half of RSV-Related Deaths in Hospitalized Adults Occur After Discharge
5


